, Tracking Stock Market Picks
Enter Symbol:
Rating: REGN
Buy $700
up 15.00 %

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reiterated to Buy with price target $700 by Canaccord Genuity

Wednesday,  Aug 5, 2015  11:25 AM ET by Lynn Gilbert

Canaccord Genuity reiterated Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Buy with price target $700. Previously, Canaccord Genuity rated Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Buy with
price target $600 on 05/20/2015, when the stock price was valued at $513.47. Since then, Regeneron Pharmaceuticals, Inc.'s stock price has gained 15% as of 08/05/2015's recent price of $592.80.
If you had followed Canaccord Genuity's previous recommendation on REGN, you would have gained 15% of your investment in 77 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy